By lowering the expression of genes involved in de novo lipogenesis, such as SREBP-1c, FAS, and ACC1, and by guarding against oxidative stress, inflammation, and steatosis—all of which are critical elements in the development of the disease—sililymarin improves lipid metabolism in NAFLD (169, 170). The gene discussed is FAS; the disease is steatosis.